Jamie L. Handlos's research while affiliated with Arizona State University and other places

What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.

It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.

If you're a ResearchGate member, you can follow this page to keep up with this author's work.

If you are this author, and you don't want us to display this page anymore, please let us know.

Publication (1)

Figure 1. Treatment of patients with CAR immune cells. In the first...
Figure 2. Metabolically fit chimeric antigen receptor (CAR) cells need...
Figure 3. Targeting of tumor cells by T cells and NK cells. T cells and...
Summary of TME mediated modulation of immunometabolism.
Engineering Metabolism of Chimeric Antigen Receptor (CAR) Cells for Developing Efficient Immunotherapies
Article
Full-text available
  • Mar 2021
Chimeric antigen receptor (CAR) T cell-based therapies have shown tremendous advancement in clinical and pre-clinical studies for the treatment of hematological malignancies, such as the refractory of pre-B cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and large B cell lymphoma (LBCL). However, CAR T cell therapy fo...
Cite
Download full-text

Citations

... Previous studies have shown that stably CAR expressing NKs can be achieved through lentiviral and retroviral expressional systems [61]. Others have also reported the use of nonviral expression systems for this purpose [62][63][64]. ...
Reference: Cancer immunotherapy via stem cell-derived NK cells
View full-text